Articles tagged with High Throughput Screening
Researchers developed a high-throughput assay to analyze CAR-T cells' effects on 3D tumor spheroid models using plate-based image cytometry. This study demonstrates the potential benefits of this method for assessing potency, specificity, and location of CAR-T cells in relation to spheroids.
A new automated algorithm enhances the assessment of human neuron survival in synucleinopathy by tracking cell death and markers of neuronal fitness. The developed method offers improved accuracy and consistency compared to manual counting.
Researchers at ETH Zurich have developed a new method called pharmacoscopy to test treatment options for multiple myeloma patients. This high-throughput screening platform analyzes the reactions of cancer cells to various treatments, offering personalized therapeutic strategies.
A University of Houston team has discovered new biomarkers for early detection of bladder cancer, including D-dimer and IL-8, which may identify disease progression. The study's findings could lead to a simple urine test as the new standard for bladder cancer diagnosis.
Researchers at Oregon State University have created a new model for evaluating potential cervical cancer drugs. The study, led by Kaitlin Fogg, enables the simultaneous and rapid testing of multiple drug compounds, opening the door to large-scale screenings that can uncover new therapies and personalized medicine options.
The March special issue of SLAS Discovery introduces protocol articles highlighting detailed scientific methods and procedures in drug discovery. The issue covers topics such as 3D imaging, cancer treatments, and high-throughput screening, emphasizing transparency and rigor in research methodology.
The SLAS Discovery Editor's Top 10 for 2022 showcases articles on COVID-19 drug discovery, 3D organoid systems, and treatments for diseases such as autism spectrum disorder and obesity. These top articles demonstrate the impact of high-throughput screening approaches and innovative technologies in advancing scientific collaboration.
A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with spinocerebellar ataxia type 5 (SCA5), a rare and debilitating disease. The pipeline uses cutting-edge spectroscopy to examine the interaction between mutant β-III-spectrin and actin, i...
The article analyzes digital microfluidics' (DMF) benefits for bacterial protocols, highlighting its versatility and potential applications in synthetic biology and diagnostics. DMF's electrostatic forces manipulate microdroplets on a plate, enabling sample preparation and nucleic acid detection.
A new high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of ERAP1 has been developed, demonstrating improved stability, reproducibility, and robustness compared to existing assays. The assay's ability to detect other difficult targets makes it a valuable tool in drug discovery.
Researchers developed an integrated approach to accelerate drug discovery by combining complex datasets from two screening platforms and next-generation metabolomics analysis. The new framework identified known compounds, confirmed mechanisms of action, and discovered novel compounds with unique biological signatures.
Few studies utilize high-throughput screening (HTS) and high-content screening (HCS) techniques in anti-obesity drug discovery due to a lack of original data or experimental design information. This limits the development of effective pharmaceutical treatments for obesity-related diseases.
Researchers have developed a new method to detect metal impurities in high-throughput screening, reducing false positive hits and saving time and resources. The technique uses acoustic mist ionization mass spectrometry to identify eight different metal contaminants, outperforming previous methods.
The use of computational tools and new strategies is transforming drug discovery, enabling researchers to navigate the vast chemical space more efficiently. Companies are leveraging virtual libraries of compounds and advanced technologies like artificial intelligence and machine learning to optimize screens and identify promising leads.
Researchers have developed a method to chart the first-ever map of allosteric sites in two common human proteins, revealing they are abundant and identifiable. This could lead to safer, smarter, and more effective medicines by targeting these 'secret doors'.
Researchers developed an AI-driven image analysis pipeline that identified novel cellular hallmarks of Parkinson's disease from images of over a million skin cells. The platform can distinguish between patient cells and healthy controls, revealing new signatures for potential therapeutic targets.
Researchers develop a method called Cell Painting that uses morphological profiling to detect side effects of substances on cells, enabling the identification of tubulin-modulating compounds. The study reveals over 1% of tested substances have this effect, including previously unknown reference substances.
Researchers proposed rational design of nanocatalysts using metal-support interaction descriptor, identifying optimal balance between adhesion and cohesion energies. This theory guides the design of ultrastable heterogeneous metal nanocatalysts, overcoming sintering issues and improving productivity.
Researchers have identified a molecule that slows cells' production of alpha-synuclein, a protein forming toxic aggregates in Parkinson's brains. The compound, A-443654, also reduces cell stress and may help degrade existing alpha-synuclein aggregates.
Researchers developed lab-grown cochlear organoids to screen FDA-approved drugs for hair cell-inducing properties. The study identified Regorafenib as a potent stimulator of hair cell formation, even regenerating lost cells in mouse tissues.
The European Lead Factory uses microscale thermophoresis to prioritize small molecule hits from high-throughput screening, improving the efficiency of drug discovery. This technology measures biomolecule movement through temperature gradients and avoids spurious mechanisms that can lead to costly failures.
Scientists at Scripps Research Institute have developed a device called LIGHTSABR that can screen millions of compounds in a week for about $500. The device overcomes technical challenges in miniaturized screening and allows users to adjust the dose of the compound being tested.
Researchers at Mahidol University have created a rapid prenatal test for diagnosing alpha-thalassemia. The new assay boasts high sensitivity and specificity, as well as a decreased risk of contamination, making it suitable for large-scale screening in Southeast Asia.
A new screening approach can accurately profile compounds in large chemical libraries, speeding the production of data for biological activities and identifying potential drug targets. This advance enables a more complete pharmacological characterization of compounds than traditional methods.
The University of Pittsburgh has been awarded $9 million to develop research tools for drug discovery as part of NIH's Roadmap initiative. The Molecular Libraries Screening Centers Network aims to accelerate medical discoveries by conducting high-throughput screenings of molecules.
By applying combinatorial techniques, scientists can test thousands of polymeric materials in a single experiment, reducing the time and effort required to develop new materials. This technology has the potential to revolutionize fields such as biomedical and electronic engineering.